Observational studyJournal of clinical laboratory analysis2025
Multimarker Approach: An Effective Tool in the Risk Stratification of Patients Admitted to the Emergency Department.
Observational study in Journal of clinical laboratory analysis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Soluble Urokinase Plasminogen Activator Receptor (suPAR): Role in the Risk Stratification of Potentially Infected Patients Presenting at the Emergency Department.Diagnostics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe use of biomarkers in emergency room decision-making has significantly increased, particularly during the COVID-19 pandemic, due to urgent clinical needs. SARS-CoV-2 infection presents a spectrum of symptoms, from asymptomatic cases to severe pneumonia with respiratory failure. During the pandemic, various prognostic tools and biomarkers have been used to quickly guide patients to appropriate care upon admission. This study evaluated the effectiveness of a multimarker approach for early risk stratification of patients with confirmed SARS-CoV-2 infection in the Emergency Department. It aimed to determine if a combined biomarker panel could better predict COVID-19 severity than single biomarkers, aiding in clinical decision-making and resource management.
methodsThis retrospective observational study analyzed data from 265 patients with suspected COVID-19 admitted to the Emergency Department at the University Hospital Tor Vergata in Rome from April to December 2020. SARS-CoV-2 infection was confirmed by RT-PCR swabs. Clinical features and biomarker levels were analyzed, and mortality prediction was assessed using ROC curve analysis to determine the AUC.
resultsResults demonstrated that the predictive power for mortality increased when multiple biomarkers were considered together. The most comprehensive panel, combining MR-proADM, CRP, D-dimer, LDH, and CT score, achieved the highest accuracy (AUC: 0.866), outperforming any individual marker.
conclusionCombining multiple biomarkers improved the prediction of disease severity over individual biomarkers. These findings suggest that using a comprehensive biomarker panel can more accurately predict SARS-CoV-2 severity, supporting its potential utility for early risk stratification in various emergency settings and aiding in the efficient allocation of healthcare resources.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.